Medicine and Dentistry
Rectum Cancer
100%
Surgery
37%
Radiation Therapy
28%
Chemotherapy
28%
Neoadjuvant Therapy
26%
Chemoradiotherapy
25%
Disease
23%
Colon Carcinoma
22%
Disease Free Survival
18%
Neoplasm
16%
Rectum Resection
14%
Recurrent Disease
13%
Rectum Carcinoma
13%
Metastatic Carcinoma
13%
Crohn's Disease
13%
Overall Survival
12%
Malignant Neoplasm
12%
Surgeon
11%
Colon
10%
Consolidation Chemotherapy
10%
Cancer Therapy
10%
FOLFOX
10%
Colorectal Surgery
9%
Total Mesorectal Excision
9%
Oncology
8%
Pelvis
8%
Anus Carcinoma
8%
Surgical Anastomosis
7%
Surgical Margin
7%
Adjuvant Chemotherapy
7%
Colectomy
6%
Fistula
6%
Inflammatory Bowel Disease
6%
Metastatic Colorectal Cancer
6%
Local Excision
6%
Magnetic Resonance Imaging
6%
Peroperative Complication
6%
Ileum
5%
Minoxidil
5%
Chemoradiation Therapy
5%
Treatment Response
5%
Preoperative Treatment
5%
Proctocolectomy
5%
Lymph Node
5%
Primary Tumor
5%
Colitis
5%
Ileo-Anal Pouch
5%
Ulcerative Colitis
5%
Keyphrases
Colorectal Cancer
90%
Short-course Radiation Therapy
23%
Colon Cancer
23%
Total Neoadjuvant Therapy
22%
Chemotherapy
20%
NCCN Guidelines
20%
Colorectal Surgery
19%
Disease-free Survival
16%
Crohn's Disease
14%
Nonoperative Management
14%
Metastatic Disease
13%
Rectal Adenocarcinoma
13%
Chemoradiation
12%
Neoadjuvant Chemoradiotherapy (nCRT)
12%
Clinical Complete Response
11%
Inflammatory Bowel Disease
11%
Locally Advanced Rectal Cancer
11%
Oncology
11%
Resection
11%
Proctectomy
10%
Neoadjuvant
10%
Overall Survival
10%
Surgical Management
10%
Consolidation Chemotherapy
9%
Transanal Total Mesorectal Excision (taTME)
9%
Surgeons
8%
Adjuvant Chemotherapy
8%
Complete Response
8%
Metastatic Colorectal Cancer (mCRC)
8%
Organ Preservation
8%
Neoadjuvant Therapy
8%
FOLFOX Chemotherapy
8%
Phase II Trial
8%
Clinical Practice Guidelines
8%
Anal Carcinoma
8%
Ileal Pouch-anal Anastomosis
8%
Rectum
8%
Ileal Crohn's Disease
7%
Survivorship
7%
Recurrent Disease
7%
Preoperative Chemotherapy
7%
Ileum
7%
Paneth Cells
6%
Pathological Stage
6%
Chemoradiotherapy
6%
MFOLFOX6
6%
Tumor
6%
Systemic Therapy
6%
Nonclinical
6%
Radiotherapy
6%